2 unknown, 1 not yet recruiting, 1 recruiting, 1 terminated. 5 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Unknown 2, Not yet recruiting 1, Recruiting 1, Terminated 1 |
| Phase 1 | 2 | Recruiting 1, Terminated 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Multiple Myeloma Progression: new trials by email Literature Review of Multiple Myeloma Progression trials Research Report on Multiple Myeloma Progression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple Myeloma. Teclistamab (Tec) and Pomalidomide (Pom) - Multiple Myeloma Progression | Phase 2 | Not yet recruiting | Odense University Hospital | 50 | 2026-09-01 | 2026-08-11 |
| Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma BCMA/GPRC5D CAR-T cells - Multiple Myeloma, Multiple Myeloma in Relapse | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 60 | 2025-04-29 | 2025-06-22 |
| Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma Rivaroxaban, ASA - Multiple Myeloma in Relapse, Multiple Myeloma Progression | Phase 2 / Phase 3 | Unknown | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 57 | 2019-01-17 | 2024-02-29 |
| Tinostamustine Conditioning and Autologous Stem Cell Tinostamustine, Autologous Stem Cell Transplant (ASCT) - Multiple Myeloma in Relapse, Multiple Myeloma Progression | Phase 1 / Phase 2 | Terminated | Mundipharma-EDO GmbH | 6 | 2018-10-15 | 2021-06-18 |
| Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans Pomalidomide - Multiple Myeloma in Relapse, Multiple Myeloma Progression | Phase 2 | Unknown | Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado | 18 | 2018-09-01 | 2018-11-14 |
Multiple Myeloma (4) · Autoimmune Diseases (1) · Disease Progression (1) · Neoplasms, Plasma Cell (1) · Recurrence (1)
Blood Protein Disorders (4) · Cardiovascular Diseases (4) · Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Hemorrhagic Disorders (4) · Hemostatic Disorders (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphoproliferative Disorders (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Paraproteinemias (4) · Vascular Diseases (4) · Neoplasms, Plasma Cell (3) · Disease Attributes (1)
pomalidomide (2) · Aspirin (1) · Cyclophosphamide (1) · Dexamethasone (1) · Focal Adhesion Protein-Tyrosine Kinases (1) · Rivaroxaban (1) · tinostamustine (1)
Essen Biotech (1) · Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · Mundipharma-EDO GmbH (1) · Odense University Hospital (1)
Norway (2) · Canada (1) · China (1) · Denmark (1) · Estonia (1) · Finland (1) · Mexico (1) · Switzerland (1) · United States (1)
Dagmar Hess (1) · Martha Louzada, MD (1) · Parameswaran Hari, MD (1)
PMID 15189396, PMID 15842354, PMID 18094721, PMID 20637084, PMID 22409262, PMID 23903204, PMID 26986753, PMID 34582035
2018 (1), 2025 (1)